Get a Sample
Schedule a Meeting
Get a Sample
Table Of Content
August 2025
The global liquid biopsy market size is calculated at USD 7.05 billion in 2025 and is forecasted to reach around USD 22.69 billion by 2034, accelerating at a CAGR of 13.91% from 2025 to 2034. The liquid biopsy market is gaining momentum as a transformative tool in oncology, driven by rising cancer cases, demand for early diagnosis, and advancements in genomic technologies. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The global liquid biopsy market size was estimated at USD 6.17 billion in 2024 and is anticipated to reach around USD 22.69 billion by 2034, expanding at a CAGR of 13.91% from 2025 to 2034.
AI is significantly improving the liquid biopsy industry by enhancing early cancer detection, disease monitoring, and even personalized treatment strategies. AI can integrate information from numerous sources, including proteomics, genomics, and imaging, to offer a more comprehensive view of the disorder, contributing to more accurate diagnoses. AI can predict treatment results and detect patients who are most likely to respond to specific therapies, permitting personalized treatment plans. AI-based liquid biopsies are crucial to understanding the promise of precision oncology, where treatments are monitored to the individual patient's specific genetic along with molecular profile.
The U.S. liquid biopsy market size was estimated at USD 2.11 billion in 2024 and is expected to hit around USD 7.32 billion by 2034 with a CAGR of 13.91% from 2025 to 2034.
Based on region, North America held the revenue share of 45.59% in 2024. This is mainly due to the increased adoption of the liquid biopsy in the North American region for the diagnosis of cancer. The rapidly growing cases of cancer in the huge market like US has resulted in the dominance of this region in the global liquid biopsy market. According to the American Cancer Society, in 2020, there were around 1.8 million new cancer cases were estimated in US.
Why Asia Pacific region will grow faster in the liquid biopsy market?
On the other hand, Asia Pacific is estimated to be the fastest-growing market during the forecast period. Asia Pacific is characterized by the increasing disposable income, increasing healthcare expenditure, rising awareness regarding the liquid biopsy techniques, and rising adoption of the advanced techniques in the hospitals, clinics, and diagnostic laboratories for the diagnosis. The growing penetration of hospitals and diagnostic centers in the region is expected to fuel the growth of the liquid biopsy market during the forthcoming years.
U.S. Liquid Biopsy Market Trends
The liquid biopsy market in the U.S. accounted for the largest market revenue share in North America in 2024, which is fueled by a well-developed technological innovation and growing clinical use. Clinical acceptance has been fast-tracked with the recent U.S. FDA approval of liquid biopsy tests to use in the early detection of cancer, selection of cancer therapies, and monitoring. Moreover, the availability of market players and research institutes creates a competitive atmosphere that leads to advancements in terms of the sensitivity and specificity of the assay. Market growth is further enhanced through strategic alliances, mergers, or acquisitions within the diagnostics industry.
Japan Liquid Biopsy Market Trends
The Japanese liquid biopsy market is expected to grow at a rapid CAGR over the forecast period, backed by governmental efforts and research-oriented investment to fight the increasing cancer cases. Grants have been offered to institutions and companies in the country to hasten the development and implementation of liquid biopsy instruments. As the population of Japan gets older and the number of people with cancer remains a problem, it is increasingly necessary to have early and precise means of diagnostics. The government support of personalized medicine, as well as the improvement of the public-private partnership, is likely to reinforce the presence of Japan in the Asia Pacific liquid biopsy market further.
Europe Liquid Biopsy Market Trends
The liquid biopsy market in Europe is expected to grow at an exponential CAGR during the forecast period, backed by the growth in regulatory approvals, the growth in cancer prevalence, and high levels of government support for advanced diagnostics. The use of liquid biopsy assays is likewise gaining traction in the clinical setting, with the European Medicines Agency (EMA) and other national regulatory bodies endorsing the use of the assays in a wider clinical practice within oncology. The trend towards the replacement of invasive tissue with liquid biopsy-based solutions, generally more comfortable to patients, monitored in real-time, and allow early detection of mutation, is gaining momentum in the region.
The UK liquid biopsy market is expected to increase at a large CAGR throughout the forecast period due to a well-developed healthcare system. A few pilot projects and trials are underway to justify the utilization of liquid biopsy in regular population screening. The joint efforts of universities, biotechnology companies, and government institutions are stimulating the production and marketing of the next-generation liquid biopsy technologies. Moreover, the UK government has paid attention to precision medicine and its financial climate of cancer research in the country, which contributes to innovation and the speed of product approvals.
The liquid biopsy market holds remarkable importance in modern healthcare because of its potential for early cancer detection, enhanced patient outcomes, and personalized treatment strategies. It provides a less invasive option to traditional tissue biopsies, permitting for repeated monitoring of disorder progression and even response to therapy. Liquid biopsies offer valuable insights into the genetic profile of a tumor, permitting oncologists to choose the most effective treatment for individual patients.
This personalized approach to cancer treatment reduces unnecessary treatments and even maximizes the chances of successful results. The market is anticipated to expand thus as liquid biopsies become more broadly adopted in clinical practice and even new applications are discovered. Researchers at the University of Chicago have studied and developed a more sensitive liquid biopsy test that uses RNA in place of DNA for detecting cancer.
The global liquid biopsy market is primarily driven by the rising prevalence of cancer among the global population and rising awareness regarding the availability of different non-invasive treatments. As per the data provided by the International Agency for Research on Cancer in the GLOBOCAN 2020 estimates, around 19.3 million new cases of cancer and around 10 million deaths were reported due to cancer in 2020. The rising prevalence of breast cancer among the female population has made it the most common type of cancer diagnosed across the globe. In 2020, around 2.3 million new breast cancer cases were recorded, closely followed by the lungs cancer, colorectal cancer, and prostate cancer. Cancer is the second most leading cause of death across the globe, as per the World Health Organization. There are several benefits associated with the new liquid biopsy technique such as rapid results, low cost, early prognosis, overcoming tumor heterogeneity, low risk, and non-invasiveness. All these benefits of the liquid biopsy over the traditional diagnosis is fueling the adoption of the liquid biopsy among the patients across the globe, and is expected to significantly drive the demand during the forecast period.
The increased awareness about the cancer is boosting the liquid biopsy market growth as liquid biopsy technique can detect the cancer early, can monitor progression of tumor, and can assess clinical prognosis. Moreover, the proliferation of advanced technologies has boosted the demand for the non-invasive diagnosis and treatments that is expected to spur the demand for the liquid biopsy in the forthcoming years. The rising investments by the market players in the clinical trials for the development of innovative diagnostic solutions is exponentially contributing towards the market growth.
| Report Highlights | Details |
| Market Size in 2025 | USD 7.05 Billion |
| Market Size by 2034 | USD 22.69 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 13.91% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | By Product, By Technology |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Growing Prevalence of Cancer and Need for Early Identification
The global liquid biopsy industry is motivated by an increase in the cases of many types of cancer, such as lung, breast, colorectal, and prostate cancer. As the number of cancer cases in the world keeps increasing, there is a need to search for ways to find cancer earlier, so that it increases the chances of treatment and survival. The liquid biopsy can be non-invasive, highly effective as an alternative to conventional tissue biopsies, reliably allowing the early detection of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and other cancer markers within the blood and other body fluids. As the world continues to focus on the development of sophisticated diagnostic tools and personalized cancer treatment, the liquid biopsies market is getting popular.
High Expenses and Limited Reimbursement Guidelines
The liquid biopsy methods commonly involve the use of expensive technology sets, such as next-generation sequencing (NGS) and biomarker-detecting solutions, which are costly. Such costs reduce accessibility, especially in low- and middle-income countries whose healthcare budget is limited. The absence of clearly defined reimbursement parameters would raise concerns among healthcare professionals about suggesting a liquid biopsy. Absence of standardized pricing models as well as clinical validation of some cancer types also further hampers adoption. Besides, cost-cutting policies are of primary importance to the majority of healthcare systems, which may become an obstacle to the adoption of new, premium-priced diagnostic technologies.
Developments in Precision Medicine and Biomarker Technologies
The exploration of circulating tumor cells, circulating tumor DNA, and extracellular vesicles is enhancing the sensitivity, specificity, and clinical usefulness of liquid biopsy tests. Such innovations provide an opportunity to detect tumor-specific changes more precisely and monitor their response to treatment and progression in real-time. Accurate medicine utilizes these possibilities to personalize cancer treatment on the basis of a specific genetic make-up of a person, making it more efficient and causing fewer side effects. Due to the increasing focus on personalized oncology as one of the central factors in cancer care, pharmaceutical and diagnostic companies are putting their efforts into developing liquid biopsy technology to efficiently develop targeted treatments.
The test/service segment was reached at $1,093.28 million in 2024. The growth can be accredited to the rising demand for the test/service.
The kits and consumables segment was reached at $2,867.07 million in 2024 and growing at a notable CAGR over the forecast period 2025 to 2034. The growth can be accredited to the rising demand for kit, due to inaccessibility of direct laboratories with infrastructure to undertake the liquid biopsy tests of most of the patients in need, the liquid biopsy market excessively relies on the distance collection of samples by transporting the diagnostics kits to the patient.
Based on the technology, the next generation sequensing segment accounted highest revenue share in 2024. This is attributed to the higher efficiency of the NGS technology to detect even the lower frequency variants of cancer. The advancements in the NGS has resulted in the increased adoption of this technology as it can detect rare and novel mutations of cancer easily.
The NGS segment dominating and fastest-growing in the liquid biopsy market in 2024. This is basically due to its ability to determine multiple genes simultaneously, offering a comprehensive view of tumor mutations along with enabling personalized medicine approaches. NGS data assists in selecting the most specific therapies for individual patients, contributing to more effective and also personalized treatment strategies. NGS-based liquid biopsy tests are taking clinical validation, with few receiving FDA acceptance as companion diagnostics.
On the other hand, the PCR is estimated to be the most opportunistic segment during the forecast period. The adoption of PCR is rising owing to its rising uses for numerous purposes such as detecting fungal infections, bacterial infections, gene mapping, and other genomic applications. The quick and real-time diagnostic results provided by the PCR tests is accurate and it can guide the targeted therapies for the cancer treatment. The PCR is gaining immense popularity and is expected to witness a significant growth rate in the upcoming years.
The clinical segment dominated and fastest-growing in the liquid biopsy market in 2024. Liquid biopsies are increasingly utilized in oncology for early cancer detection, therapy monitoring, treatment selection, and recurrence surveillance. They provide a less invasive option to traditional tissue biopsies, permitting for repeated monitoring along with early detection of cancer. Continued advancements in technologies such as next-generation sequencing (NGS) and even bioinformatics is enhancing the sensitivity together with accuracy of liquid biopsy analysis, thus fueling market expansion.
The urine segment is the fastest growing in the liquid biopsy market during the forecast period. They are recognized for their non-invasive nature along with convenience, mainly in diagnosing as well as monitoring urological cancers. Ease of collection, non-invasiveness, and even the existence of exfoliated cells, cfDNA, proteins, and other biomarkers relevant to urological cancers.
The global liquid biopsy market (by clinical application) is currently being dominated by treatment monitoring. The growth can be accounted to the increased awareness and adoption of liquid biopsy tests for the early detection and treatment of cancer. The increase in the prevalence of the geriatric disease is witnessed, thus increasing the adoption of non-invasive biopsies.
The clinical segment dominated and fastest-growing in the liquid biopsy market in 2024. Liquid biopsies are increasingly utilized in oncology for early cancer detection, therapy monitoring, treatment selection, and recurrence surveillance. They provide a less invasive option to traditional tissue biopsies, permitting for repeated monitoring along with early detection of cancer. Continued advancements in technologies such as next-generation sequencing (NGS) and even bioinformatics is enhancing the sensitivity together with accuracy of liquid biopsy analysis, thus fueling market expansion.
The prognosis and recurrence monitoring segment will hit reach at notable CAGR over the forecast period. Some of the companies providing liquid biopsy techniques for the prognosis and reoccurrence monitoring of the disease are adaptive biotechnologies and pathway genomics, among others.
Based on the application, the cancer segment dominated the global liquid biopsy market in 2024, in terms of revenue and is estimated to sustain its dominance during the forecast period. This is simply attributed to the increased adoption of the liquid biopsy techniques for the diagnosis of various types of cancer. The increased prevalence of cancer cases among the global population has boosted the growth of the cancer segment. According to the International Agency for Research on Cancer, the most prevalent types of cancer includes lungs cancer, breast cancer, prostate cancer, and colorectal cancer. The cancer cases across the globe is estimated to rise by 47% from 2020 to 2040, and the number of cancer cases are estimated to be 28.4 million by 2040 across the globe. Hence, this is expected to sustain the significance of this segment throughout the forecast period.
The breast cancer segment is the fastest growing in the liquid biopsy market during the forecast period. Breast cancer is one of the most common type of cancers worldwide, making it a significant target for diagnostic tools such as liquid biopsies. Liquid biopsies, which involve determining blood samples, are less invasive as well as more patient-friendly than tissue biopsies, which need tissue removal. This choice for non-invasive procedures is a key contributor for the acceptance of liquid biopsies in breast cancer management.
Based on the circulating biomarker, the circulating tumor cells segment dominated the market with the revenue share in 2024. The circulating tumor cells have gained rapid traction in the market as the liquid biopsy is considered as the most reliable method of detecting circulating tumor cells. Moreover, it facilitates in cancer prognosis, and can guide in the cancer therapeutics and monitor therapeutic regimens.
The circulating tumor cells was reached $1,857.08 million in 2024. The growth can be accredited to the rising demand for the CTCs biomarker for the early detection of cancer by performing non-invasive biopsies.
Circulating tumor cells or CTCs are the cells, which are being shed from the cancer tumor and are then circulated through the bloodstream. The advancements in the technologies, which help in the detection of CTCs from different body fluids have permitted the early detection of different types of cancers through minimal invasive techniques. The probable risk of cancer is mainly determined through the subsequent outgrowth of different tumor cells in new micro-environments of the body. Detecting CTCs and extracting required data still proves to be a tough approach due to their low concentrations in biological fluids. Their detection and characterization require highly sensitive instruments. The process of detecting CTCs includes enrichment of cell culture, purification, detection, and analysis of the sample.
The real-time liquid biopsy through CTCs analysis includes the collection of peripheral blood samples from the patient who is to be diagnosed. Later, the CTC enrichment is done by using both the physical properties (size, density, electric charges, and deformability) and the biological properties (cell surface protein expression and viability). After the enrichment of the sample, CTCs are needed to be identified from the blood mixture (mixture of leukocytes and CTCs). The detection can be carried out by making the use of protein-based or mRNA-based staining assays.
The developments in in-vivo techniques enable to bypass the limitation of the low concentration of CTCs. With the use of nano detectors, the samples with appreciable CTC concentration can be prepared for further analysis.
On the other hand, the circulating tumor DNA is expected to be the fastest-growing segment during the forecast period. The circulating tumor DNA helps in the early detection of the cancer and its mutation. It is most efficient in detection of the breast cancer. Therefore, the rising prevalence of breast cancer is expected to boost the growth of this segment. As per the GLOBOCAN report, breast cancer has surpassed the lungs cancer as the most diagnosed type of cancer across the globe in 2020.
The Cell-Free DNA segment was reached $2,583.65 million in 2024. The growth can be accredited to the rising demand for cfDNA kits due to easier isolation of cfDNA in the bloodstream owing to early detection of cancer by liquid biopsy test.
The cell-free DNA segment is expected to grow at a significant CAGR over the forecast period. With the continued growth of the sensitivity of next-generation sequencing and the development of new methods of bioinformatics tools, low-frequency mutations have been detected more frequently, making cfDNA an effective biomarker of early diagnoses, minimal residual disease (MRD), and monitoring of therapies. Increased precision medicine and the potential to predict emerging mutations and resistance markers increase clinical relevance as well because these factors can guide clinical efforts using precision medicine approaches. Moreover, the concept of genetic testing based on cfDNA is gaining popularity in the field of its usefulness in most cancer types, and is being applied to standard clinical practices.
The cell-free segment is the fastest growing in the liquid biopsy market during the forecast period. It aims to determine DNA fragments circulating in the bloodstream which have been released from tumor cells. It is a rapidly growing area because of its potential for early cancer detection along with monitoring treatment response. Innovations in next-generation sequencing (NGS) along with artificial intelligence are thus driving its growth.
The test/services contributed the most revenue in 2024 and are expected to dominate throughout the projected period. Such services are in the form of complete genomic profiling, mutation monitoring, and ctDNA, CTCs, and other molecular signatures in blood, urine, or saliva. The test/service providers have provided a sophisticated testing platform based on next-generation sequencing (NGS), digital PCR, and useful bioinformatics applications to facilitate a high level of sensitivity and specificity of the genetic changes detected related to cancer. The increase in the personalization of treatment schedules and real-time disease tracking has compelled pharmaceutical and diagnostic organizations to create customized, specific assays for individual cancer types. These tests are highly scalable and convenient in comparison to conventional tissue biopsies; thus, they are especially attractive in oncology contexts.
The kits and consumable segment is the fastest growing in the liquid biopsy market during the forecast period. The rising adoption of liquid biopsy for cancer screening, therapy selection, as well as recurrence monitoring, along with the growth of precision oncology, is driving the need for these kits and consumables.
By Technology
By Usage
By Types of Sample
By Circulating Biomarker
By Products
By Indication Type
By Clinical Application
By Region
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
August 2025
May 2025
November 2024
July 2025